OPEN ORPHAN #ORPH – Result of AGM July 21, 2021 – Posted in: Blog, Open Orphan (ORPH) – Tags: CEO Cathal Friel, clinical research organisation, human challenge clinical trials, Open Oprhan (ORPH), pharmaceutical services, Result of AGM, vaccine and antiviral testing
21 July, 2021
Open Orphan plc
(“Open Orphan”, the “Company”)
Result of Annual General Meeting
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that at the Annual General Meeting held at 12 noon today, all resolutions were duly passed.
For further information please contact:
|
Open Orphan plc |
+353 (0) 1 644 0007 |
|||
|
Cathal Friel, Executive Chairman |
||||
|
Arden Partners plc (Nominated Adviser and Joint Broker) |
+44 (0) 20 7614 5900 |
|||
|
John Llewellyn-Lloyd / Richard Johnson / Oscair McGrath |
||||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
|||
|
Geoff Nash / James Thompson/ Richard Chambers |
||||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
Anthony Farrell |
||||
|
Walbrook PR (Financial PR & IR) |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com |
|||
|
Paul McManus/ Sam Allen/ Louis Ashe-Jepson |
+44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |
|||